MRK
Merck & Co., Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+26/100
Last price
141.18
▲ 1.64 (1.18%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
140.26
Prev close
139.54
Day high
142.16
Day low
139.75
Volume
8.07M
Market cap
$350.19B
P/E (TTM)
112.65
52W range
82.01 – 156.92
Day trading desk
Gap from prior close
+0.52%
Prior close 139.54
VWAP
141.61
-0.30% from price
Relative volume
1.42×
Normal
Session range
1.88%
139.54 – 142.16
Position in range
63%
Mid range
ATR (14D)
3.54
2.50% of price
Prior day high
144.06
PDH
Prior day low
138.80
PDL
Bid / ask spread
—
Quote not published
Session volume
13.89M
Avg 9.79M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.92%
-6.9%
1M
-5.58%
-6.7%
3M
+12.66%
+8.1%
6M
+19.00%
+0.8%
YTD
+34.85%
+20.6%
1Y
+59.14%
+42.7%
3Y
+37.87%
-44.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MRK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-51.24K
Net selling
Buy transactions
16
177.00K shares
Sell transactions
7
228.24K shares
Net transactions
+23
Buys less sells
Sell : buy shares
1.3 : 1
Mixed
Insider-held shares
1.38M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 13, 26 | GUINDO CHIRFI Officer |
SELL | 10.00K | $1.35M | Direct |
| Aug 12, 26 | ZACHARY JENNIFER L General Counsel |
SELL | 80.31K | $10.72M | Direct |
| Aug 12, 26 | DELUCA RICHARD ROBERT JR. Officer |
SELL | 45.32K | $5.94M | Direct |
| Aug 12, 26 | ZACHARY JENNIFER L General Counsel |
CONVERSION | 54.93K | $6.03M | Direct |
| Aug 6, 26 | GUINDO CHIRFI Officer |
SELL | 15.00K | $1.97M | Direct |
| Aug 6, 26 | DELUCA RICHARD ROBERT JR. Officer |
SELL | 6.05K | $788.77K | Direct |
| Aug 5, 26 | MARALDO DAVID R. Officer |
SELL | 18.71K | $2.41M | Direct |
| Aug 5, 26 | WILLIAMS DAVID MICHAEL Chief Technology Officer |
SELL | 52.85K | $6.81M | Direct |
| Aug 5, 26 | MARALDO DAVID R. Officer |
CONVERSION | 18.71K | $1.54M | Direct |
| Aug 5, 26 | WILLIAMS DAVID MICHAEL Chief Technology Officer |
CONVERSION | 52.85K | $3.94M | Direct |
| May 1, 26 | SMART DALTON E. III Officer |
CONVERSION | 383 | $42.96K | Direct |
| May 1, 26 | MARALDO DAVID R. Officer |
CONVERSION | 552 | $61.91K | Direct |
| Apr 30, 26 | SMART DALTON E. III Officer |
CONVERSION | 1.41K | $155.35K | Direct |
| Apr 30, 26 | LARSON BETTY D Officer |
— | 13.44K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHATTOPADHYAY SANAT |
Officer | 200.68K | Conversion of Exercise of derivative security |
DAVIS ROBERT M |
Chief Executive Officer | 450.35K | Conversion of Exercise of derivative security |
DELUCA RICHARD ROBERT JR. |
Officer | 110.17K | Sale |
GUINDO CHIRFI |
Officer | 36.61K | Sale |
LI DEAN Y |
Officer | 94.43K | Conversion of Exercise of derivative security |
LITCHFIELD CAROLINE |
Chief Financial Officer | 92.30K | Conversion of Exercise of derivative security |
OOSTHUIZEN JOHANNES JACOBUS |
Officer | 21.89K | Conversion of Exercise of derivative security |
ROMANELLI JOSEPH EDWARD |
Officer | 28.74K | Stock Award(Grant) |
WILLIAMS DAVID MICHAEL |
Chief Technology Officer | 31.72K | Conversion of Exercise of derivative security |
ZACHARY JENNIFER L |
General Counsel | 45.51K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$350.19B
Enterprise value$397.01B
Revenue (TTM)$66.57B
Gross profit$50.53B
EBITDA$28.87B
Net income$3.17B
EPS (TTM)$1.26
Free cash flow$15.17B
Total cash$7.14B
Total debt$53.91B
Book value / share$16.99
Shares outstanding2.47B
Float2.46B
Short % of float1.40%
Dividend yield2.44%
Beta (5Y)0.22
Valuation & profitability ratios
Trailing P/E112.65
Forward P/E14.99
PEG ratio2.55
Price / sales—
Price / book8.36
EV / revenue5.96
EV / EBITDA13.75
Gross margin75.90%
Operating margin-0.24%
Profit margin4.77%
Return on equity6.96%
Return on assets11.87%
Debt / equity128.41
Current ratio1.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $65.01B | $64.17B | $60.12B | $59.28B | +1.3% |
| Operating revenue | $65.01B | $64.17B | $60.12B | $59.28B | +1.3% |
| Cost of revenue | $16.38B | $15.19B | $16.13B | $17.41B | +7.8% |
| Gross profit | $48.63B | $48.98B | $43.99B | $41.87B | -0.7% |
| Research & development | $15.79B | $17.94B | $30.53B | $13.55B | -12.0% |
| Selling, general & admin | $10.73B | $10.82B | $10.50B | $10.04B | -0.8% |
| Total operating expense | $26.52B | $28.75B | $41.03B | $23.59B | -7.8% |
| Operating income | $22.11B | $20.22B | $2.95B | $18.28B | +9.3% |
| Net interest income | -$1.01B | -$856.00M | -$781.00M | -$805.00M | -18.5% |
| Pre-tax income | $21.07B | $19.94B | $1.89B | $16.44B | +5.7% |
| Tax provision | $2.80B | $2.80B | $1.51B | $1.92B | +0.0% |
| Net income | $18.25B | $17.12B | $365.00M | $14.52B | +6.6% |
| Net income to common | $18.25B | $17.12B | $365.00M | $14.52B | +6.6% |
| Basic EPS | 7.38 | 6.77 | 0.14 | 5.73 | +8.9% |
| Diluted EPS | 7.28 | 6.74 | 0.14 | 5.71 | +8.0% |
| EBIT | $22.42B | $21.21B | $3.04B | $17.41B | +5.7% |
| EBITDA | $28.26B | $25.71B | $6.91B | $21.32B | +9.9% |
| Basic shares | 2.47B | 2.53B | 2.61B | 2.53B | -2.1% |
| Diluted shares | 2.51B | 2.54B | 2.61B | 2.54B | -1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $14.56B | $13.24B | $6.84B | $12.69B | +10.0% |
| Cash & short-term investments | $14.56B | $13.69B | $7.09B | $13.19B | +6.4% |
| Accounts receivable | $11.78B | $10.28B | $10.35B | $9.45B | +14.6% |
| Inventory | $6.66B | $6.11B | $6.36B | $5.91B | +9.0% |
| Total current assets | $43.52B | $38.78B | $32.17B | $35.72B | +12.2% |
| Property, plant & equipment | $25.32B | $23.78B | $23.05B | $21.42B | +6.5% |
| Goodwill & intangibles | $48.26B | $38.04B | $39.21B | $41.47B | +26.9% |
| Total assets | $136.87B | $117.11B | $106.67B | $109.16B | +16.9% |
| Total current liabilities | $28.33B | $28.42B | $25.69B | $24.24B | -0.3% |
| Current debt | $2.59B | $2.65B | $1.37B | $1.95B | -2.3% |
| Long-term debt | $46.75B | $34.46B | $33.68B | $28.75B | +35.7% |
| Total debt | $49.34B | $37.11B | $35.05B | $30.69B | +32.9% |
| Total liabilities | $84.20B | $70.73B | $69.04B | $63.10B | +19.0% |
| Retained earnings | $73.08B | $63.07B | $53.90B | $61.08B | +15.9% |
| Shareholder equity | $52.61B | $46.31B | $37.58B | $45.99B | +13.6% |
| Working capital | $15.19B | $10.36B | $6.47B | $11.48B | +46.6% |
| Net tangible assets | $4.35B | $8.28B | -$1.63B | $4.52B | -47.5% |
| Shares issued | 3.58B | 3.58B | 3.58B | 3.58B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $18.26B | $17.13B | $377.00M | $14.53B | +6.6% |
| Depreciation & amortisation | $5.84B | $4.50B | $3.87B | $3.91B | +29.8% |
| Stock-based compensation | $820.00M | $761.00M | $645.00M | $541.00M | +7.8% |
| Change in working capital | -$6.98B | -$3.67B | -$2.21B | -$2.78B | -90.2% |
| Operating cash flow | $16.47B | $21.47B | $13.01B | $19.09B | -23.3% |
| Capital expenditure | -$4.11B | -$3.37B | -$3.86B | -$4.39B | -21.9% |
| Investing cash flow | -$13.74B | -$7.73B | -$14.08B | -$4.96B | -77.7% |
| Share buybacks | -$5.08B | -$1.31B | -$1.35B | $0 | -289.3% |
| Dividends paid | -$8.18B | -$7.84B | -$7.45B | -$7.01B | -4.3% |
| Financing cash flow | -$1.92B | -$7.03B | -$4.81B | -$9.12B | +72.7% |
| Free cash flow | $12.36B | $18.10B | $9.14B | $14.71B | -31.7% |
| End cash position | $14.69B | $13.32B | $6.91B | $12.77B | +10.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $16.61B | $16.29B | $16.40B | $17.28B | $15.81B | +2.0% |
| Operating revenue | $16.61B | $16.29B | $16.40B | $17.28B | $15.81B | +2.0% |
| Cost of revenue | $4.39B | $4.20B | $5.55B | $3.85B | $3.56B | +4.8% |
| Gross profit | $12.21B | $12.09B | $10.85B | $13.42B | $12.25B | +1.0% |
| Research & development | $9.74B | $12.59B | $3.89B | $4.23B | $4.05B | -22.6% |
| Selling, general & admin | $2.90B | $2.70B | $2.90B | $2.63B | $2.65B | +7.6% |
| Total operating expense | $12.64B | $15.29B | $6.78B | $6.87B | $6.70B | -17.3% |
| Operating income | -$433.00M | -$3.20B | $4.07B | $6.55B | $5.55B | +86.5% |
| Net interest income | -$490.00M | -$444.00M | -$342.00M | -$231.00M | -$236.00M | -10.4% |
| Pre-tax income | -$683.00M | -$3.53B | $3.42B | $6.75B | $5.00B | +80.7% |
| Tax provision | $654.00M | $709.00M | $458.00M | $958.00M | $571.00M | -7.8% |
| Net income | -$1.33B | -$4.24B | $2.96B | $5.79B | $4.43B | +68.5% |
| Net income to common | -$1.33B | -$4.24B | $2.96B | $5.79B | $4.43B | +68.5% |
| Basic EPS | -0.54 | -1.72 | 1.20 | 2.33 | 1.77 | +68.5% |
| Diluted EPS | -0.54 | -1.72 | 1.19 | 2.32 | 1.76 | +68.6% |
| EBIT | -$158.00M | -$3.06B | $3.83B | $7.07B | $5.30B | +94.8% |
| EBITDA | $1.43B | -$1.54B | $6.30B | $8.23B | $6.42B | +192.4% |
| Basic shares | 2.47B | 2.47B | 2.47B | 2.49B | 2.50B | -0.0% |
| Diluted shares | 2.47B | 2.47B | 2.49B | 2.50B | 2.51B | -0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.85B | $5.33B | $14.56B | $18.17B | $8.01B | +28.6% |
| Cash & short-term investments | $7.14B | $5.70B | $14.56B | $18.21B | $8.62B | +25.2% |
| Accounts receivable | $12.56B | $12.21B | $11.78B | $12.12B | $11.85B | +2.9% |
| Inventory | $6.21B | $6.48B | $6.66B | $6.44B | $6.60B | -4.2% |
| Total current assets | $36.68B | $35.02B | $43.52B | $47.56B | $37.06B | +4.8% |
| Property, plant & equipment | $25.74B | $25.43B | $25.32B | $25.64B | $25.24B | +1.2% |
| Goodwill & intangibles | $46.56B | $47.33B | $48.26B | $36.90B | $36.78B | -1.6% |
| Total assets | $129.80B | $128.69B | $136.87B | $129.55B | $117.52B | +0.9% |
| Total current liabilities | $27.73B | $26.95B | $28.33B | $28.63B | $26.04B | +2.9% |
| Current debt | $2.83B | $2.44B | $2.59B | $1.41B | $1.43B | +15.6% |
| Long-term debt | $51.08B | $46.67B | $46.75B | $39.97B | $33.97B | +9.4% |
| Total debt | $53.91B | $49.12B | $49.34B | $41.37B | $35.40B | +9.8% |
| Total liabilities | $87.82B | $82.75B | $84.20B | $77.64B | $68.46B | +6.1% |
| Retained earnings | $63.27B | $66.72B | $73.08B | $72.23B | $68.48B | -5.2% |
| Shareholder equity | $41.93B | $45.88B | $52.61B | $51.85B | $48.99B | -8.6% |
| Working capital | $8.95B | $8.07B | $15.19B | $18.93B | $11.03B | +10.9% |
| Net tangible assets | -$4.63B | -$1.45B | $4.35B | $14.95B | $12.21B | -219.5% |
| Shares issued | 2.47B | 3.58B | 3.58B | 3.58B | 3.58B | -31.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.34B | -$4.24B | $2.96B | $5.79B | $4.43B | +68.5% |
| Depreciation & amortisation | $1.58B | $1.51B | $2.47B | $1.15B | $1.12B | +4.7% |
| Stock-based compensation | $298.00M | $185.00M | $205.00M | $204.00M | $216.00M | +61.1% |
| Change in working capital | $423.00M | -$1.61B | -$2.32B | $1.31B | -$2.26B | +126.2% |
| Operating cash flow | $5.37B | $3.92B | $2.86B | $7.82B | $3.29B | +37.1% |
| Capital expenditure | -$893.00M | -$991.00M | -$1.03B | -$987.00M | -$764.00M | +9.9% |
| Investing cash flow | -$5.60B | -$10.21B | -$11.20B | -$283.00M | -$770.00M | +45.1% |
| Share buybacks | -$757.00M | -$874.00M | -$1.25B | -$1.32B | -$1.34B | +13.4% |
| Dividends paid | -$2.14B | -$2.10B | -$2.02B | -$2.03B | -$2.08B | -1.9% |
| Financing cash flow | $1.76B | -$2.98B | $4.75B | $2.64B | -$3.56B | +159.1% |
| Free cash flow | $4.48B | $2.93B | $1.82B | $6.83B | $2.53B | +53.0% |
| End cash position | $6.89B | $5.40B | $14.69B | $18.26B | $8.07B | +27.7% |
Options analytics
Put / call volume
0.76
Call-heavy session
Put / call open interest
0.19
Positioning, not flow
Max pain
137.00
-3.5% from spot
ATM implied vol
30.8%
Nearest strike to spot
Skew (10% OTM)
+8.8%
Puts bid over calls
Call volume
1.75K
Contracts, this expiry
Put volume
1.32K
Contracts, this expiry
Heaviest call OI
152.50
1.94K contracts
Heaviest put OI
147.00
299 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.26 | -0.13 | +49.4% |
| Mar 2026 | -1.47 | -1.28 | +13.1% |
| Dec 2025 | 2.01 | 2.04 | +1.5% |
| Sep 2025 | 2.35 | 2.58 | +9.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.17 | 18 | $17.32B | +0.2% |
| Next quarter | 1.95 | 18 | $16.84B | +2.7% |
| Current year | 2.72 | 25 | $67.11B | +3.2% |
| Next year | 9.45 | 24 | $70.15B | +4.5% |
Analyst targets & ownership
Mean target$156.36
High target$186.00
Low target$105.00
Implied upside10.75%
Analyst count25
ConsensusBUY
Strong buy / Buy5 / 14
Hold8
Sell / Strong sell0 / 0
Held by insiders0.06%
Held by institutions83.04%
Institutions holding4.80K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
145.77
-3.15% from price
SMA 20
146.09
-2.84% from price
SMA 50
142.68
-0.52% from price
SMA 100
132.06
+6.90% from price
SMA 200
123.28
+15.14% from price
EMA 12
145.03
-2.66% from price
EMA 26
145.24
-2.79% from price
EMA 50
141.97
-0.56% from price
RSI (14)
43.4
Neutral
MACD (12,26,9)
-0.21
Hist -1.20
ATR (14)
3.54
2.49% of price
Realised vol 30D
24.3%
Annualised
Bollinger upper
151.65
20, 2σ
Bollinger lower
140.54
20, 2σ
50 / 200 cross
Golden
142.68 vs 123.28
Trend bias
Above 200
+15.14%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.17
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
24.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-11.9%
Peak to trough
Max drawdown 5Y
-44.7%
Peak to trough
ATR 14
3.54
2.49% of price
Beta (reported)
0.22
5Y monthly, from filing
Short interest
Shares short
34.43M
Prior 24.51M
Change vs prior
+40.5%
Shorts adding
% of float
1.40%
Normal
% of shares out
1.40%
Against total outstanding
Days to cover
3.1
Liquid
Float
2.46B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Sep 29, 26 | Scotiabank | MAINTAINED | Sector Outperform | Sector Outperform |
| Sep 10, 26 | HSBC | MAINTAINED | Buy | Buy |
| Sep 9, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Sep 8, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 4, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 25, 26 | Wolfe Research | MAINTAINED | Outperform | Outperform |
| Aug 25, 26 | Argus Research | MAINTAINED | Buy | Buy |
| Aug 21, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Aug 20, 26 | BMO Capital | MAINTAINED | Outperform | Outperform |
| Aug 20, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 20, 26 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
Dividends & splits
Forward rate$3.40 / yr
Forward yield2.44%
5-year avg yield2.89%
Payout ratio266.67%
Ex-dividend dateSep 15, 2026
Next pay dateOct 7, 2026
Last split1048:1000
Split dateJun 3, 2021
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-04
Annual report of employee stock purchase
11-K · 2026-06-24
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-28
Corporate Changes & Voting Matters
8-K · 2026-05-22
Tender Offer/Acquisition Reports
SC TO-T/A · 2026-05-05
Periodic Financial Reports
10-Q · 2026-05-04
Corporate Changes & Voting Matters
8-K · 2026-04-30
Headlines
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
Zacks · 5h ago
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
Investor's Business Daily · 5h ago
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?
Zacks · 12h ago
Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results
Quartz · 13h ago
2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges
StockStory · 15h ago
Pfizer’s $6.49 Billion Prevnar Franchise Faces a New Challenger
TIKR · 20h ago
Stock Market Today: Dow Gains, Nasdaq Hits New High; Shopify, Brazil Plays Offer Entries
Investor's Business Daily · 1d ago
MRNA Stock Soars Ahead Of Slated Return To Nasdaq-100; Retail Echoes Valuation Concerns
Stocktwits · 1d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.